Diabetes is
a chronic disease that affects more than 8.5 percent of the world's population.
It is critical to check blood glucose levels (BGLs) on a regular basis in order
to track the evolution of diabetes. Non-Invasive Blood Glucose Monitoring
Devices use a painless approach to track a patient's glucose level on a
continuous basis. Non-invasive blood glucose monitoring devices require fewer
finger sticks and allow data to be easily transferred and shared for further
analysis. Patients can use these gadgets at home to monitor their blood glucose
levels. Noninvasive glucose monitoring reduces the need for unpleasant
pricking, which increases the risk of infection and increases the amount of
damage to the finger tissue.
Non Invasive Diabetes Therapy Market
Dynamics
According to
the World Health Organization, the diabetes population will increase to 336
million by 2030, up from 270 million in 2015. The need for non-invasive
treatment is predicted to rise as the incidence rate of diabetics rises,
creating favourable market possibilities for competitors around the world.
Furthermore, expanding healthcare access and focusing on R&D could boost
the non-invasive diabetes therapy market's overall size. Some businesses are working on
developing non-invasive systems based on photonics and occlusion spectroscopy.
Changes in
macroeconomics and consumer preferences will continue to drive the market. In
underdeveloped countries, healthcare costs have risen. For early entrants, a
large consumer base combined with changing lifestyles is projected to provide
significant new market opportunities.
Non Invasive Diabetes Therapy Market
Impact of COVID-19 Pandemic
The COVID-19
pandemic has had an impact on a variety of businesses and markets, including
the global market for non-invasive diabetic therapy. Following the outbreak in
December 2019, many nations closed their borders and briefly halted
international travel. Physical distancing requirements were introduced, causing
manufacturing activity to be disrupted. Furthermore, statewide lockdown regulations
had a large negative impact on the worldwide supply chain sector, which
hampered the global non-invasive diabetes therapy market severely. However, the
introduction of vaccines and a decrease in the number of cases are likely to
help the industry eventually recover.
Comments
Post a Comment